Sana Biotechnology Inc (SANA)

$8.09

+0.16

(+2.02%)

Market is closed - opens 7 PM, 24 Apr 2024

Performance

  • $8.00
    $8.32
    $8.09
    downward going graph

    1.11%

    Downside

    Day's Volatility :3.79%

    Upside

    2.71%

    downward going graph
  • $2.75
    $12.00
    $8.09
    downward going graph

    66.01%

    Downside

    52 Weeks Volatility :77.08%

    Upside

    32.58%

    downward going graph

Returns

PeriodSana Biotechnology IncSector (Health Care)Index (Russel 2000)
3 Months
52.07%
1.9%
0.0%
6 Months
171.48%
10.7%
0.0%
1 Year
60.83%
4.6%
-1.1%
3 Years
-61.71%
14.2%
-22.1%

Highlights

Market Capitalization
1.7B
Book Value
$1.45
Earnings Per Share (EPS)
-1.46
Wall Street Target Price
11.17
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-29.44%
Return On Equity TTM
-72.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-302.3M
Diluted Eps TTM
-1.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.21
EPS Estimate Next Year
-1.37
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Sana Biotechnology Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
7
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 38.07%

Current $8.09
Target $11.17

Technicals Summary

Sell

Neutral

Buy

Sana Biotechnology Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sana Biotechnology Inc
Sana Biotechnology Inc
-11.0%
171.48%
60.83%
-61.71%
-61.71%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sana Biotechnology Inc
Sana Biotechnology Inc
NA
NA
NA
-1.21
-0.72
-0.29
NA
1.45
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sana Biotechnology Inc
Sana Biotechnology Inc
Buy
$1.7B
-61.71%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    11.34%
  • FMR Inc

    7.15%
  • Canada Pension Plan Investment Board

    4.62%
  • Baillie Gifford & Co Limited.

    4.60%
  • Vanguard Group Inc

    4.44%
  • BlackRock Inc

    3.84%

Corporate Announcements

  • Sana Biotechnology Inc Earnings

    Sana Biotechnology Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou

Organization
Sana Biotechnology Inc
Employees
328
CEO
Dr. Steven D. Harr M.D.
Industry
Services

FAQs